March 29th 2023
Co-editor-in-Chief Howard S. Hochster, MD, highlights the most exciting developments from the 2023 Gastrointestinal Cancer Symposium hosted by the American Society of Clinical Oncology (ASCO).
January 25th 2023
Investigators Identify Significant Racial Disparities in Surgical Care for Cancers of the GI TractApril 8th 2022
Black patients were reported to be significantly less likely to receive standard of care surgical treatment for cancer of the gastrointestinal tract compared with White patients.
The Emerging Value of ctDNA in Colon Cancer Adjuvant Therapy DecisionsMarch 10th 2022
In this month’s Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, reviews results of the CIRCULATE-Japan clinical trial that were presented at the 2022 Gastrointestinal Cancers Symposium.
Phase 3 Trial of NUC-1031/Cisplatin Discontinued for Advanced Biliary Tract CancerMarch 5th 2022
NUC-1031 plus cisplatin was unlikely to reach a primary end point of improved overall survival in advanced biliary tract cancer, leading to the discontinuation of the phase 3 NuTide:121 trial.
177Lu-Dotatate Yields Clinically Relevant But Non-Significant OS Benefit for Midgut NETsFebruary 27th 2022
Patients with advanced midgut neuroendocrine tumors experienced a clinically relevant improvement in median overall survival when treated with 177Lu-Dotatate compared with the control of high-dose long-acting octreotide, although the difference was not significant.
First-Line Nivolumab Combos Yield Improved OS Vs Chemo Alone in Esophageal CancerFebruary 22nd 2022
The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.
Zev A. Wainberg, MD, Highlights the Rationale for Examining Long-Term Data From Pembrolizumab/Chemo in Advanced Gastric/GEJ AdenocarcinomaJanuary 29th 2022
Zev A. Wainberg, MD, spoke to the rationale for examining the efficacy of pembrolizumab alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.
First-Line Tislelizumab/Chemotherapy Improved OS in PD-L1–Expressing Locally Advanced Unresectable/Metastatic Gastric or GEJ CancerJanuary 27th 2022
Tislelizumab met the primary end point of overall survival in the phase 3 RATIONALE 305 trial in a population of patients with locally advanced unresectable/metastatic gastric or gastroesophageal junction cancer with a PD-L1–expressing tumor in the first-line setting.
Hong Kong Department of Health Approves Pemigatinib for Adults With FGFR2+ Locally Advanced/Metastatic CholangiocarcinomaJanuary 25th 2022
Pemigatinib is a new treatment option following approval from the Hong Kong Department of Health for patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement following progression on at least 1 prior line of therapy.
Clinical Benefit Yielded With Pembrolizumab and Chemotherapy in Esophageal/GEJ AdenocarcinomaJanuary 22nd 2022
The quality of life was maintained for patients with esophageal cancer plus including gastroesophageal junction adenocarcinoma when treated with pembrolizumab plus chemotherapy.
Updated CheckMate 649 Results Show Sustain Benefit of Nivolumab Plus Chemo for Gastric/GEJ CancerJanuary 22nd 2022
Nivolumab in combination with chemotherapy was beneficial vs chemotherapy alone in patients with gastric or gastroesophageal junction cancer at a follow-up of at least 24 months.
Addition of Best Supportive Care to Pembrolizumab Significantly Improved Survival for Advanced HCCJanuary 21st 2022
Patients with advanced hepatocellular carcinoma achieved a statically significant and clinically meaningful survival benefit following treatment with pembrolizumab and best supportive care in the second line.
High Rates of Disease Control Derived in Pretreated PDAC and Other GI Malignancies With Adagrasib MonotherapyJanuary 21st 2022
Updated results from a cohort of the KRYSTAL-1 trial spotlight the potential of adagrasib for patients with previously treated KRAS G12C¬–mutant gastrointestinal tumors.
Investigators Gain Insights Into AE Risks Associated With Nivolumab for Advanced Gastric Cancer Through Markers in Gut MicrobiomeJanuary 21st 2022
Risks of skin-related adverse events from nivolumab may be predicted by the presence of Arthrobacter and fatty acid metabolism pathways in the gut microbiome of patients with advanced gastric cancer.
Nivolumab Plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for MSI/dMMR Oeso-Gastric AdenocarcinomaJanuary 21st 2022
Patients with resectable microsatellite instable/mismatch repair–deficient oeso-gastric junction adenocarcinoma experienced a high rate of pathologic complete response following treatment with neoadjuvant nivolumab and ipilimumab followed by adjuvant nivolumab.
Zev A. Wainberg, MD, on Findings From the Updated KEYNOTE-062 Trial With Pembrolizumab/Chemo for Advanced Gastric/GEJ AdenocarcinomaJanuary 21st 2022
In an interview with CancerNetwork® during the 2022 Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, discussed key updates from the phase 3 KEYNOTE-062 trial, examining pembrolizumab plus or minus chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.
FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ CancersJanuary 18th 2022
CYNK-101 plus standard frontline chemotherapy, trastuzumab, and pembrolizumab has received a fast track designation from the FDA for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.